JPRN-jRCT2080225306CompletedPhase 2
A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Rozibafusp Alfa (AMG 570) in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Amgen K.K.
- Enrollment
- 320
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized Masking: None (Open Label) Intervention Model: Parallel Assignment This is a Bayesian adaptive phase 2b, multi-center, double-blind, randomized, placebo-controlled, 52-week, dose-ranging study in subjects with active SLE and inadequate response to SOC therapies including oral corticosteroids (OCS), immunosuppressants and immunomodulators.
Eligibility Criteria
- Ages
- >= 18age old to <= 75age old (—)
- Sex
- All
Inclusion Criteria
- •Inclusion Criteria Screening Visit:
- •1. Subject has provided informed consent prior to initiation of any study-specific activities/procedures.
- •2. Age >= 18 years to <= 75 years at screening visit.
- •3. Fulfills classification criteria for SLE according to the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for SLE (Aringer et al, 2019), with antinuclear antibody >= 1:80 by immunofluorescence on Hep-2 cells being present at screening.
- •4. Hybrid SLEDAI score >= 6 points with a Clinical hSLEDAI score >= 4 points. The Clinical hSLEDAI is the hSLEDAI assessment score without the inclusion of points attributable to laboratory results, including urine or immunologic parameters.
- •Additional protocol-specific rules are applied at screening and throughout the study, as follows:
- •- Arthritis: Arthritis (at least 3 tender and swollen joints) must involve joints in the hands or wrists for the hSLEDAI scoring.
- •- Alopecia: Subjects should have hair loss without scarring; should neither have alopecia areata nor androgenic alopecia; and should have a CLASI activity score for alopecia >= 2.
- •- Oral ulcers: Ulcers location and appearance must be documented by the investigator.
- •- Scleritis and Episcleritis: the presence of stable SLE-related scleritis and episcleritis must be documented by an ophthalmologist and other causes excluded.
- •- Renal: subjects with urine protein/creatinine ratio < 3000 mg/g (or equivalent method) in a clear catch spot urine sample can enroll and be scored in the hSLEDAI, provided the subject has a clinical hSLEDAI >= 4 and did not receive induction treatment for nephritis within the last year.
- •- Pleurisy and Pericarditis: symptoms of pleurisy and pericarditis must be accompanied by objective findings to be scored in the hSLEDAI.
- •5. Unless there is a documented intolerance, subjects must be taking:
- •- Only 1 of the following SLE treatments: anti-malarial (hydroxychloroquine, chloroquine, or quinacrine), azathioprine, methotrexate, leflunomide, mycophenolate mofetil/acid mycophenolic, or dapsone.
- •- 2 of the above-mentioned SLE treatments in which 1 must be anti-malarial (hydroxychloroquine, chloroquine, or quinacrine).
- •- Treatment should be taken for >= 12 weeks prior to screening and must be a stable dose for >= 8 weeks prior to screening.
- •6. For subjects taking OCS, dose must be <= 20 mg/day of prednisone or OCS equivalent, and the dose must be stable at baseline visit for >= 2 weeks prior to screening visit.
Exclusion Criteria
- •Exclusion Criteria Screening Visit
- •Subjects are excluded from the study if any of the following criteria apply:
- •Disease Related:
- •1. Urine protein creatinine ratio >= 3000 mg/g (or equivalent) at screening or induction therapy for lupus nephritis within 1 year prior to screening visit.
- •2. Active CNS lupus within 1 year prior to screening including, but not limited to, aseptic meningitis, ataxia, CNS vasculitis, cranial neuropathy, demyelinating syndrome, optic neuritis, psychosis, seizures, or transverse myelitis.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Efficacy and Safety of Efavaleukin Alfa in Subjects with Active Systemic LupusErythematosusEUCTR2020-003509-72-PLAmgen Inc.320
Active, not recruiting
Phase 2
Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus ErythematosusActive Systemic Lupus ErythematosusJPRN-jRCT2041210076Kimura Takeshi320
Active, not recruiting
Phase 1
Efficacy and Safety of Efavaleukin Alfa in Subjects with Active Systemic LupusErythematosusActive Systemic Lupus ErythematosusEUCTR2020-003509-72-BGAmgen Inc.320
Active, not recruiting
Phase 1
A Study to Evaluate the Efficacy and Safety of Rozibafusp Alfa (AMG 570) in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) TherapyActive Systemic Lupus Erythematosus (SLE)MedDRA version: 21.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2019-000328-16-PTAmgen Inc320
Active, not recruiting
Phase 1
Efficacy and Safety of Efavaleukin Alfa in Subjects with Active Systemic Lupus ErythematosusActive Systemic Lupus ErythematosusMedDRA version: 21.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemicSystem Organ Class: 100000004859EUCTR2020-003509-72-ITAMGEN INC.320